Author/Authors :
Rafiei Tabatabaei, Sedigheh Pediatric lnfections Research Center, Research Institute for children’s Health - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Shariatpanahi, Ghazal School of Medicine, Bahrami Hospital - Tehran University of Medical Sciences, Tehran, Iran , Azadkiya, Romina Pediatric lnfections Research Center, Research Institute for children’s Health - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Karimzadeh, Parvaneh Pediatric Neurology Research Center - Research Institute for Children’s Health - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Karimi, Abdollah Pediatric lnfections Research Center, Research Institute for children’s Health - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Guillain-Barré syndrome (GBS) is characterized by a monophasic, ascending, and symmetrical paralysis with areflexia that progresses over days to weeks. It is typically a postinfectious autoimmune process that leads to destruction of myelin. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan, China, in late 2019 and rapidly spread around the world, causing a pandemic of novel coronavirus disease 2019 (COVID-19). There have been scattered reports of adults with possible GBS and concurrent evidence of COVID-19, but no previous reports in children. The patient is an 8-year-old boy who presented to the emergency department with progressive, ascending weakness with areflexia. He was intubated for airway protection because of poor secretion control. MRI of the spine revealed abnormal enhancement of posterior nerve roots. A lumbar puncture revealed albuminocytologic dissociation with 1 nucleated cell per mm3 and a protein level of 620 mg/dL. Electrodiagnostic findings were compatible with sensorimotor demyelinating polyneuropathy. The lumbar puncture, MRI, and electrodiagnostics were all consistent with GBS. Results of SARS-CoV-2 nucleic acid amplification and SARS-CoV-2 immunoglobulin G antibody tests were positive. Treatment was initiated with intravenous immunoglobulin; he received a total of 2 g/kg. His neurologic examination revealed improvement in the subsequent days. He was extubated after 4 days of intubation. This case is the first reported case of a child with GBS in the setting of an acute COVID-19 infection. This case reveals the wide scope of presentations of COVID-19 and postinfectious processes. Clinicians should constantly have a high level of suspicion for COVID-19.
